Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Free Cash Flow (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Free Cash Flow for 8 consecutive years, with -$71.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow fell 78.43% year-over-year to -$71.8 million, compared with a TTM value of -$241.9 million through Sep 2025, down 18.83%, and an annual FY2024 reading of -$166.0 million, down 161.12% over the prior year.
  • Free Cash Flow was -$71.8 million for Q3 2025 at Bicycle Therapeutics, up from -$73.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $33.8 million in Q2 2023 and bottomed at -$87.0 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$30.7 million, with a median of -$31.8 million recorded in 2022.
  • The sharpest move saw Free Cash Flow surged 320.38% in 2021, then tumbled 2537.0% in 2024.
  • Year by year, Free Cash Flow stood at -$12.2 million in 2021, then plummeted by 161.01% to -$31.8 million in 2022, then plummeted by 49.07% to -$47.3 million in 2023, then soared by 79.37% to -$9.8 million in 2024, then crashed by 635.84% to -$71.8 million in 2025.
  • Business Quant data shows Free Cash Flow for BCYC at -$71.8 million in Q3 2025, -$73.3 million in Q2 2025, and -$87.0 million in Q1 2025.